Krsnaa Diagnostics has announced the results for the first six months ending September 30, 2021, following its listing on the stock exchanges on August 16, 2021. In H1FY2022, revenue from operations has been registered at Rs 241 crores, up 19 per cent y-o-y. The company posted, EBITDA of Rs 74 crores, up 76 per cent y-o-y. EBITDA margins increased to 30.9 per cent in H1 FY22 as compared to 20.9 per cent in H1 FY21. Profit After Tax without CCPS was at Rs 34 crores, up by 167 per cent with margins of 13.8 per cent. Net cash position was at Rs 326 crores at the end of September 2021.

Core business i.e. radiology and pathology registered a revenue increase of 143 per cent y-o-y, which was partially offset by a decline of 75 per cent during COVID-19. The core business contribution was 89 per cent whereas COVID-19 business contributed 11 per cent to the total revenues in H1 FY22.

Yash Mutha, Executive Director, Krsnaa Diagnostics said, "The year 2021 marks a significant milestone for Krsnaa Diagnostics in its growth story, the as the company went public in August 2021. I would like to thank all our employees, partners and shareholders who have showed confidence in our business model and joined us in fulfilling our mission ‘To make a difference in the healthcare diagnostic industry."